Evidence map›Paper›PMID 42539377›Full record

ReviewBioengineering & translational medicine2026

Engineering autoimmune disease models using organoids: Harnessing microenvironmental engineering for precision medicine and immunological recapitulation.

Chang-Jin Lee, Yeojin Kim, Misu Kim, Yeri Alice Rim, Ji Hyeon Ju

Abstract readReview
In one paragraph

Review in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chang-Jin LeeDepartment of Medical Sciences Graduate School of The Catholic University of Korea Seoul Republic of Korea.ORCID https://orcid.org/0000-0003-4629-8052
Yeojin KimYiPSCELL Inc. Seoul Seocho-gu Republic of Korea.ORCID https://orcid.org/0000-0003-0877-7415
Misu KimYiPSCELL Inc. Seoul Seocho-gu Republic of Korea.ORCID https://orcid.org/0009-0003-1168-1075
Yeri Alice RimCiSTEM Laboratory, Catholic iPSC Research Center, Seoul St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul Republic of Korea.ORCID https://orcid.org/0000-0001-9541-3075
Ji Hyeon JuCiSTEM Laboratory, Catholic iPSC Research Center, Seoul St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul Republic of Korea.ORCID https://orcid.org/0000-0002-1381-5466

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune diseases-including systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA)-are increasingly understood as programmable microenvironmental states, wherein evolving changes in matrix mechanics, barrier integrity, interferon and cytokine networks, immune-complex deposition, and stromal-immune reciprocity progressively reshape tissue behavior. These shifting axes generate nonlinear trajectories of fibrosis, vascular injury, and joint destruction that static or reductionist in vitro systems fail to recapitulate. Organoid and organ-on-a-chip platforms now allow controlled reconstruction of these dynamic microenvironments in human-derived systems. By integrating iPSC-derived epithelial, endothelial, stromal, and immune lineages with tunable extracellular matrix (ECM) stiffness and viscoelasticity, perfusable microvasculature, and modular innate and adaptive immune components, these systems reproduce key autoimmune phenomena. These include stiffness-driven fibroblast activation and endothelial-to-mesenchymal transition (EndoMT), interferon-conditioned barrier collapse, immune-complex-mediated injury, and cytokine-dependent stromal invasion. Patient-specific induced pluripotent stem cell (iPSC), CRISPR-based editing of risk alleles, and controlled exposure to sera or autoantibody repertoires provide genetic and immunologic personalization, while multi-omic profiling, spatial imaging, and machine-learning analytics enable quantitative alignment between organoid states and patient tissues. By translating pathogenic microenvironmental logic into controllable 3D systems, these platforms establish autoimmune organoids as programmable, human-relevant tools for mechanistic discovery, therapeutic interrogation, and precision modeling-laying the groundwork for next-generation, potentially animal-free pipelines and advancing personalized immunology across SSc, SLE, and RA.

Indexed as

autoimmune disease modelingautoimmune organoidsiPSCprecision medicine

Identifiers

PMID42539377
PMCPMC13423613

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.